Brits Least Concerned About Swine Flu Impact on Travel PlansLONDON - Travelzoo (NASDAQ: TZOO), a global Internet media company, today announced the results of a pan-European survey conducted last week among 10,582 travellers in 24 regions across the UK, Germany, France and Spain. The survey results reveal vastly diverging attitudes towards Swine Flu, with just 7% of Brits saying they will change their travel plans because of it, compared to 21% of Spaniards, 15% of Germans and 14% of French. Computer-assisted Surgery: European Hotspot Opens in GermanyLEIPZIG, Germany - Surgery in Full HD: Leipzig is now home to the future of precise, efficient and safe high-tech surgery. The International Reference and Development Centre for Surgical Technology (IRDC) is implementing an innovative, comprehensive approach in specialty surgery. The OR system is the first to link and analyze all patient information, making it a true surgical assistant. While the minimally invasive procedure is transmitted to a surgical cockpit in Full-HD quality, detailed patient information is combined in the background - including prior diseases, inflammation markers, structures at risk, nerve conduction data and HD images from inside the body. Three-dimensional views allow perfect preparation for surgery. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII AntibodiesLACHEN, Switzerland and HOBOKEN, New Jersey - - ISTH Symposia Discuss Prevention and Eradication of FVIII Inhibitors and Introduce First Recombinant FVIII Produced From a Human Cell Line The Dangers of Inappropriate use of Propofol in the Tragic Demise of Michael JacksonLONDON - Following the tragic death of Michael Jackson and the recent news that high levels of the potent anaesthetic propofol were found in his body, the fans of Michael Jackson, the worldwide media and probably the whole world who loved his music, are wondering how this could possibly happen. Media attention has focused on the role of a physician whom is likely to have prescribed and administered it. STALLERGENES: 1st Half-Year 2009: Performance Ahead of ExpectationsPARIS - - Net Profit Up 11% - Strong Research and Investment Effort - Positive net Financial Position Medical World Recognises New Therapy for Reflux Babies (IRL)NINOVE, Belgium - 20% of parents seek medical help because of the frequent regurgitation (spitting up food) of their baby and the accompanying discomfort (crying). Reputed medical journal “Archives of Disease in Childhood” of the “British Medical Journal” group recently published the results of the clinical research project that began at the end of 2006 in the Children’s gastroenterology department of the Brussels University Hospital. Medical World Recognises New Therapy for Reflux BabiesNINOVE, Belgium - 20% of parents seek medical help because of the frequent regurgitation (spitting up food) of their baby and the accompanying discomfort (crying). Reputed medical journal “Archives of Disease in Childhood” of the “British Medical Journal” group recently published the results of the clinical research project that began at the end of 2006 in the Children’s gastroenterology department of the Brussels University Hospital. MarketsandMarkets: Top Ten Medical Device Technologies Market Worth $454.3 Billion by 2014WILMINGTON, Delaware - According to a new healthcare market research report ‘Global Top Ten Medical Device Technologies Market (2009 - 2014)’, published by MarketsandMarkets (www.marketsandmarkets.com) in 2009, the entire market for top ten medical device technologies is estimated to be approximately $454.3 billion, of which medical diagnostic devices technologies alone constitute about 40% of the entire market at approximately $177.8 billion. The market for drug delivery devices constituted an estimated $110.8 billion for the same period. Raptor Pharmaceuticals Raises US$5 MillionNOVATO, California - Raptor Pharmaceuticals Corp. (”Raptor” or the “Company”) (OTC Bulletin Board: RPTP), today announced that it has raised an aggregate US$5 million of gross proceeds through a private placement of units (”August 2009 Private Placement”) and through the exercise of warrants (the “Warrant Exchange”) originally issued in connection with its May/June 2008 private placement. The August 2009 Private Placement resulted in gross proceeds to Raptor of approximately US$2.4 million or US$2.3 million after placement agent fees and other expenses. The Warrant Exchange raised approximately US$2.6 million in net proceeds for Raptor. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership AwardTEL AVIV, Israel and SOUTHAMPTON, Pennsylvania - Mennen Medical, a leading provider of patient monitors, cardiac catheterization and electrophysiology systems, announced today that the global growth consulting company Frost & Sullivan has awarded Mennen Medical the 2009 European Patient Monitoring Technology Leadership of the Year Award. A Wound that Does Not Heal: Frost & Sullivan Reveals the Impact of Chronic Ulcers on the European Healthcare SystemLONDON - Chronic wounds cause immense suffering, healthcare expenditure, and disability for millions of patients - and make the wound care market a billion dollar market. Chronic ulcers take a prolonged duration to heal, especially when appropriate treatment is not provided. Market players in the wound management market need to thoroughly examine a wound and its impact on the patient, in order to be able to develop more advanced wound management products. HBA Global Announces Finalists for the 2009 International Package Design Awards (IPDA)NEW YORK - HBA Global Expo (www.hbaexpo.com), the leading product development event for the cosmetics, fragrance, personal care and well-being industries, has announced the finalists of its Annual International Package Design Awards (IPDA). From among these finalists the Category Winners and the Grand Award will be announced at the HBA Global Expo & Conference taking place September 15-17, 2009 at the Jacob Javits Convention Center in New York. EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 AuctionWELLESLEY HILLS, Massachusetts - Joseph F. Finn, Jr., C.P.A. (”Finn”), announced today that the PRX-00023 Therapeutics Program in Phase 2b/3 will be part of the intellectual property offered for sale at the September 30, 2009 auction. ProFibrix Raises US $11 Million (EUR 8 Million) in Series B FinancingLEIDEN, The Netherlands and SEATTLE - ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company’s Supervisory Board. Bavarian Nordic in Negotiations With the US Authorities for the Further Development of IMVAMUNE(R)KVISTGAARD, Denmark - Bavarian Nordic A/S (OMX: BAVA) announced today that the US authorities have initiated negotiations for a new contract to develop a freeze-dried version of the IMVAMUNE(R) smallpox vaccine. This potential new project will have no influence on the ongoing RFP-3 BARDA (Biomedical Advanced Research and Development Authority) contract for the procurement of 20 million doses of IMVAMUNE(R) and the licensure of the current liquid-frozen formulation, but represents an additional business opportunity. vProtect Luminal Shield (TM) from Prescient Medical Receives CE MarkDOYLESTOWN, Pennsylvania - - Novel Self-Expanding Platform for Treatment of Coronary Artery Disease Receives European Regulatory Clearance Karolinska Development Portfolio Company Launches GMP Facility for Particulate ManufacturingSTOCKHOLM - Karolinska Development (publ), managing one of the largest portfolios of life science research companies in Europe, announced that XSpray Microparticles AB has launched a GMP production facility in Malmo, Sweden. In addition to offering particle development and characterization services, XSpray can now provide customers with high quality drug particles and powders for use in their clinical studies. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug PlatformCAMBRIDGE, Massachusetts - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business. LNA technology has the benefit of a very quick validated target to proof of concept turnaround, thereby increasing the speed and lowering the cost of development. Health Robotics Receives Overwhelming Support from its Customers for its McKesson-CytoCare PartnershipBOZEN, Italy - Health Robotics today reported that on the heels of its recent partnership announcement with McKesson, it has received categorical support from virtually all of its 13 North American customers in just a few days since the partnership was publicly announced. While several customers’ hospital policies prevent them from publicly commenting on industry events, a few reactions to the McKesson-Health Robotics partnership [CytoCare Robot only] were cleared for publication. MS Society Statement - Molecule Found in Brain May Protect From Damage Caused by MSLONDON - The MS Society, the UK’s largest charity dedicated to supporting everyone affected by multiple sclerosis (MS), has responded to the news issued by the University of Bristol concerning the study of Galanin in MS. First Swedish Patients Receive MitraClip(R) TherapyMENLO PARK, California - - Use of the MitraClip(R) System Continues to Expand in Europe Charlie Buckwell Appointed Medical Communications Head, Further Advancing McCann Healthcare Worldwide’s Global CapabilitiesNEW YORK - McCann Healthcare Worldwide is re-aligning and expanding its medical communications businesses, to build a dedicated, unified and empowered medical communications network capability, with truly global reach. Chemist+Druggist Reveals Frontline NHS Staff Won’t Get Swine Flu VaccineTONBRIDGE, England - Pharmacists have branded government swine flu vaccination plans “unacceptable,” Chemist+Druggist has revealed. The criticism comes after the profession was excluded from the first wave of healthcare staff to get the jab. Distressed Patients Suffer Panic Attacks as UK Medicine Stocks Hit by Shortages, Chemist+Druggist RevealsTONBRIDGE, England - Medicine shortages have left patients extremely distressed, with some seeing their conditions deteriorate and even being admitted to hospital, a Chemist+Druggist (C+D) survey has found. Online Think Tank Big Think Launches New Multimedia Web Series Exploring Some of the Most Pressing Science and Medical Issues of our TimeNEW YORK - - World-Renowned Experts Explore the Implications and Impact of H1N1 and the Next Pandemic as well as the Debate over Personal Genomics AccuVein Sells Multiple AV300s to First European CustomerCOLD SPRING HARBOR, New York - - European Shipping of AccuVein’s Vein Illumination Device Initiated Workers Uniting Union Counters the Lies in U.S. Health Care DebateLONDON - Workers Uniting, the world’s first international union, has launched an attack on the lies and misinformation being spread in the USA by opponents of President Obama’s health insurance reform plan. Norovirus Aboard Cruise Ship Marco Polo Rapidly Eradicated by Revolutionary new Vaporisation ProcessLONDON - The cruise ship Marco Polo, whose round-Britain cruise had to be cancelled because hundreds of passengers became ill with the vomiting bug Norovirus, has been totally disinfected by SitexOrbis’ revolutionary infection control fogging service in just 5 hours at the Tilbury docks. Response to Dr Steve Boorman’s Interim Report Into the Health and Wellbeing of NHS StaffLONDON - The Work Foundation, RAND Europe and Aston Business School - the partnership trio of research organisations working closely with the review team to undertake the research and analysis of the evidence behind the Boorman Review - today (19 August 2009) welcomed publication of the interim version of the report. Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & SullivanLONDON - Increasing knowledge related to the pathology of diabetes will support the introduction of improved drugs to treat the disease. As healthcare moves towards the ideal of preventive medicine, there are a few companies conducting research on diabetes vaccines. If they succeed, the entire market landscape is bound to undergo instant change. Horst M. Rechelbacher To Deliver HBA Global Expo Keynote AddressNEW YORK - - Organic and Naturals Pioneer to Provide Insight on this US$8 Billion Industry Smith & Nephew Takes Single Injection PMA to Next StageRALEIGH and DURHAM, North Carolina - Smith & Nephew (NYSE: SNN; LSE: SN) Biologics & Spine is proceeding to the next stage in the approval process for the U.S. launch of DUROLANE(R) Single Injection, Stabilized Hyaluronic Acid. AdvanDx Closes US$8 Million Financing Round and Elects New Board MemberWOBURN, Massachusetts and VEDBAEK, Denmark - - Financing provided by existing investors SLS Venture and LD Pensions Clinical Study Proves Pollogen’s TriPollar(TM) Radio Frequency Technology is Effective in the Treatment of Stretch MarksTEL AVIV, Israel - - Results Published in the Online Edition of the Journal of Dermatological Treatment Elsevier Global Medical News Launches H1N1 ChannelMORRISTOWN, New Jersey - An H1N1 influenza channel has been added to the Elsevier Global Medical News (EGMN) wire service division of the International Medical News Group. The H1N1 channel was created to meet physicians’ continuing needs to keep up-to-date with the news about the spread of the 2009 H1N1 influenza virus, as well as the new diagnostics, vaccines, clinical trials, and treatments for H1N1 infections. |
